Johnson & Johnson said it will make a significant investment to expand the presence and capabilities of its unit Janssen Research & Development LLC in South San Francisco, Calif.

The investment aims to support the leasing and construction of a research and development facility in the global innovation center of South San Francisco.

Johnson & Johnson's Janssen BioPharma Inc. executed a lease within the Healthpeak Properties Inc.'s South San Francisco project.

The personnel at this new facility will focus on infectious and retinal diseases, along with data science research for discovery, product development and supply.

Johnson & Johnson expects that the facility will be fully operational in 2022 upon completion of construction.